PE20091656A1 - Compuestos heterociclicos como inhibidores de la cinasa raf - Google Patents
Compuestos heterociclicos como inhibidores de la cinasa rafInfo
- Publication number
- PE20091656A1 PE20091656A1 PE2009000430A PE2009000430A PE20091656A1 PE 20091656 A1 PE20091656 A1 PE 20091656A1 PE 2009000430 A PE2009000430 A PE 2009000430A PE 2009000430 A PE2009000430 A PE 2009000430A PE 20091656 A1 PE20091656 A1 PE 20091656A1
- Authority
- PE
- Peru
- Prior art keywords
- amino
- metoxy
- inhibitors
- imidazol
- pyrimidin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
SE REFIERE A COMPUESTOS HETEROCICLICOS SUSTITUIDOS DE FORMULA (I) DONDE (a) ES (i) O (ii), DONDE X E Y SON CADA UNO NR4, O U S; R4 ES H O ALQUILO OPCIONALMENTE SUSTITUIDO; R1 Y R2 SON CADA UNO HETEROARILO O HETEROCICLILO OPCIONALMENTE SUSTITUIDOS; R3 ES ALQUILO, ARILO, HETEROARILO, ENTRE OTROS, OPCIONALMENTE SUSTITUIDOS. SON COMPUESTOS PREFERIDOS: N-(2-(4-(5-(6-AMINO-5-METOXI-PIRIDIN-3-IL)-2-(4-FLUORO-FENIL)-1H-IMIDAZOL-4-IL)-PIRIMIDIN-2-IL-AMINO)-ETIL)-2-METOXI-ACETAMIDA, N-(2-(4-(4-(6-AMINO-5-METOXI-PIRIDIN-3-IL)-2-(4-(TRIFLUORO-METIL)-FENIL)-1H-IMIDAZOL-5-IL)-PIRIMIDIN-2-IL-AMINO)-ETIL)-2-METOXI-ACETAMIDA, (S)-N-(1-(4-(4-(6-AMINO-5-METOXI-PIRIDIN-3-IL)-2-(4-FLUORO-FENIL)-1H-IMIDAZOL-5-IL)-PIRIMIDIN-2-IL-AMINO)-PROPAN-2-IL)-2-METOXI-ACETAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA CINASA RAF SIENDO UTILES EN EL TRATAMIENTO DE CARCINOMA DE PULMON, CARCINOMA PANCREATICO, CARCINOMA DE COLON, MELANOMA
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3872308P | 2008-03-21 | 2008-03-21 | |
US20845809P | 2009-02-24 | 2009-02-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20091656A1 true PE20091656A1 (es) | 2009-11-20 |
Family
ID=40734805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2009000430A PE20091656A1 (es) | 2008-03-21 | 2009-03-20 | Compuestos heterociclicos como inhibidores de la cinasa raf |
Country Status (26)
Country | Link |
---|---|
US (1) | US8129394B2 (es) |
EP (1) | EP2274300A2 (es) |
JP (2) | JP5384611B2 (es) |
KR (2) | KR20130040258A (es) |
CN (1) | CN102015686B (es) |
AR (1) | AR071283A1 (es) |
AU (1) | AU2009227013B2 (es) |
BR (1) | BRPI0908906A2 (es) |
CA (1) | CA2718936A1 (es) |
CL (1) | CL2009000687A1 (es) |
CO (1) | CO6311078A2 (es) |
CR (1) | CR11681A (es) |
DO (1) | DOP2010000280A (es) |
EA (1) | EA201001456A1 (es) |
EC (1) | ECSP10010559A (es) |
IL (1) | IL208063A0 (es) |
MA (1) | MA32232B1 (es) |
MX (1) | MX2010010317A (es) |
NI (1) | NI201000156A (es) |
PE (1) | PE20091656A1 (es) |
SM (1) | SMAP201000115A (es) |
SV (1) | SV2010003673A (es) |
TW (1) | TW201000457A (es) |
UY (1) | UY31724A (es) |
WO (1) | WO2009115572A2 (es) |
ZA (1) | ZA201006505B (es) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2474545T3 (pl) | 2005-12-13 | 2017-04-28 | Incyte Holdings Corporation | Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej |
JP5483880B2 (ja) * | 2006-10-23 | 2014-05-07 | 武田薬品工業株式会社 | イミノピリジン誘導体およびその用途 |
HUE043732T2 (hu) | 2007-06-13 | 2019-09-30 | Incyte Holdings Corp | Januskináz gátló hatású (R)-3-(4-(7H pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciklopentilpropánnitril sók alkalmazása |
US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
US8865732B2 (en) * | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
US8481569B2 (en) * | 2008-04-23 | 2013-07-09 | Takeda Pharmaceutical Company Limited | Iminopyridine derivatives and use thereof |
NZ588909A (en) * | 2008-04-23 | 2012-08-31 | Takeda Pharmaceutical | Iminopyridine derivatives and use thereof |
US20110039892A1 (en) * | 2008-04-23 | 2011-02-17 | Takeda Pharmaceutical Company Limited | Iminopyridine derivative and use thereof |
AU2010249380B2 (en) | 2009-05-22 | 2015-08-20 | Incyte Holdings Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors |
CA2761954C (en) | 2009-05-22 | 2018-07-31 | Incyte Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
US8242260B2 (en) * | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
CA2784807C (en) | 2009-12-29 | 2021-12-14 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
EP3028699B1 (en) | 2010-02-25 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
AR081315A1 (es) | 2010-03-10 | 2012-08-08 | Incyte Corp | Derivados heterociclicos de piperidin y pirimidin -4-il-azetidina, una forma cristalina de la sal del acido acetonitriladipico de un derivado pirimidinico, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades relacionadas con la inhibicion de jak-1, t |
NZ603686A (en) | 2010-05-21 | 2014-11-28 | Incyte Corp | Topical formulation for a jak inhibitor |
EP2592130B1 (en) * | 2010-07-09 | 2015-01-21 | Mitsubishi Gas Chemical Company, Inc. | Photochromic material |
CA2804845A1 (en) | 2010-07-12 | 2012-01-19 | Stuart Ince | Substituted imidazo[1,2-a]pyrimidines and -pyridines |
JP5917544B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン |
EA026201B1 (ru) | 2010-11-19 | 2017-03-31 | Инсайт Холдингс Корпорейшн | Циклобутилзамещенные производные пирролопиридина и пирролопиримидина как ингибиторы jak |
US8791112B2 (en) * | 2011-03-30 | 2014-07-29 | Arrien Pharmaceuticals Llc | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors |
AR086983A1 (es) | 2011-06-20 | 2014-02-05 | Incyte Corp | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
US9498471B2 (en) | 2011-10-20 | 2016-11-22 | The Regents Of The University Of California | Use of CDK9 inhibitors to reduce cartilage degradation |
CN108542906A (zh) | 2011-11-11 | 2018-09-18 | 诺华股份有限公司 | 治疗增生性疾病的方法 |
PT2782557T (pt) | 2011-11-23 | 2018-11-26 | Array Biopharma Inc | Formulações farmacêuticas |
US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
CN103159735B (zh) * | 2011-12-10 | 2015-12-09 | 通化济达医药有限公司 | 取代的咪唑激酶抑制剂 |
JP2015503504A (ja) * | 2011-12-23 | 2015-02-02 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | ヘテロアリールおよびその使用 |
CN104470515B (zh) | 2012-05-03 | 2016-12-07 | 圣路易斯药学院 | 用于增加神经营养肽的组合物和方法 |
AR091079A1 (es) | 2012-05-18 | 2014-12-30 | Incyte Corp | Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak |
WO2014047330A1 (en) * | 2012-09-19 | 2014-03-27 | Jean-Michel Vernier | Novel raf kinase inhibitors |
PL2919766T3 (pl) | 2012-11-15 | 2021-10-04 | Incyte Holdings Corporation | Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu |
AU2014225938B2 (en) | 2013-03-06 | 2018-07-19 | Incyte Holdings Corporation | Processes and intermediates for making a JAK inhibitor |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
MX2016001639A (es) | 2013-08-07 | 2016-10-07 | Incyte Corp | Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1). |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
WO2016061144A1 (en) | 2014-10-14 | 2016-04-21 | The Regents Of The University Of California | Use of cdk9 and brd4 inhibitors to inhibit inflammation |
KR101665231B1 (ko) * | 2015-01-30 | 2016-10-13 | 순천향대학교 산학협력단 | 티오페닐 그룹을 갖는 티아졸계 화합물 및 이를 유효성분으로 포함하는 항진균제 |
BR112017016596B1 (pt) * | 2015-02-04 | 2023-01-10 | Medpacto Inc. | Composição farmacêutica para uso em um método de prevenção ou tratamento de leucemia mieloide crônica e uso do composto de fórmula química ii |
GB201614940D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Intellectual Property (No 2) Ltd | Chemical compounds |
GB201614934D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Intellectual Property (No 2) Ltd | Chemical compounds |
EP3544971B1 (en) | 2016-11-22 | 2022-07-06 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 12 (cdk12) and uses thereof |
KR102515694B1 (ko) | 2017-01-10 | 2023-03-29 | 바이엘 악티엔게젤샤프트 | 해충 방제제로서의 헤테로사이클 유도체 |
UY37557A (es) | 2017-01-10 | 2018-07-31 | Bayer Ag | Derivados heterocíclicos como pesticidas |
WO2018146253A1 (en) | 2017-02-10 | 2018-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway |
WO2019005241A1 (en) * | 2017-03-23 | 2019-01-03 | Clavius Pharmaceuticals, Llc | TRI-SUBSTITUTED IMIDAZOLES FOR INHIBITION OF TGF-BETA AND METHODS OF TREATMENT |
JP7038994B2 (ja) * | 2017-10-16 | 2022-03-22 | 国立大学法人金沢大学 | 炭素繊維強化プラスチックの製造方法、炭素繊維強化プラスチック及びセルロース系樹脂 |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
JP7416716B2 (ja) | 2017-12-28 | 2024-01-17 | トラクト ファーマシューティカルズ インコーポレイテッド | 円柱上皮幹細胞のための幹細胞培養系およびそれに関連した使用法 |
DK3746429T3 (da) | 2018-01-30 | 2022-05-02 | Incyte Corp | Fremgangsmåder til fremstilling af (1-(3-fluor-2-(trifluormethyl)isonicotinyl)piperidin-4-on) |
UA127925C2 (uk) | 2018-03-30 | 2024-02-14 | Інсайт Корпорейшн | Лікування гнійного гідраденіту з використанням інгібіторів jak |
WO2020011141A1 (zh) * | 2018-07-12 | 2020-01-16 | 深圳市塔吉瑞生物医药有限公司 | 一种二芳基吡唑化合物及包含该化合物的组合物及其用途 |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
WO2020150091A1 (en) | 2019-01-15 | 2020-07-23 | Merck Sharp & Dohme Corp. | Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection |
US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
WO2020192302A1 (zh) * | 2019-03-27 | 2020-10-01 | 广州必贝特医药技术有限公司 | 含嘧啶的三取代咪唑类化合物及其应用 |
WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
JP2023509260A (ja) | 2019-08-14 | 2023-03-08 | インサイト・コーポレイション | Cdk2阻害剤としてのイミダゾリルピリミジニルアミン化合物 |
CN115298177A (zh) | 2019-10-11 | 2022-11-04 | 因赛特公司 | 作为cdk2抑制剂的双环胺 |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
KR20230039665A (ko) | 2020-07-02 | 2023-03-21 | 바이엘 악티엔게젤샤프트 | 해충 방제제로서의 헤테로사이클 유도체 |
US11905272B1 (en) | 2023-09-12 | 2024-02-20 | King Faisal University | 3-(2-(4-methoxypyridin-3-yl)-4,5-diphenyl-1H-imidazol-1-yl)-N,N-dimethylpropan-1-amine as an anti-cancer compound |
US11932619B1 (en) | 2023-09-13 | 2024-03-19 | King Faisal University | 3-(2-(6-Methoxypyridin-3-yl)-4,5-diphenyl-1H-imidazol-1-yl)-N,N-dimethylpropan-1-amine as an anticancer compound |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3707475A (en) * | 1970-11-16 | 1972-12-26 | Pfizer | Antiinflammatory imidazoles |
JPS5613715A (en) * | 1979-07-13 | 1981-02-10 | Nec Corp | Manufacture of coil |
DE3029376A1 (de) * | 1980-07-31 | 1982-03-18 | Nepera Chemical Co. Inc., Harriman, N.Y. | Verfahren zur herstellung von 2,4,5-tris-pyridylimidazolen |
US5243517A (en) * | 1988-08-03 | 1993-09-07 | Westinghouse Electric Corp. | Method and apparatus for physiological evaluation of short films and entertainment materials |
JP2722586B2 (ja) | 1989-01-13 | 1998-03-04 | 大正製薬株式会社 | インドリルイミダゾール誘導体 |
JP2808460B2 (ja) * | 1989-11-16 | 1998-10-08 | 大正製薬株式会社 | イミダゾール誘導体 |
US6850252B1 (en) * | 1999-10-05 | 2005-02-01 | Steven M. Hoffberg | Intelligent electronic appliance system and method |
US5436830A (en) * | 1993-02-01 | 1995-07-25 | Zaltman; Gerald | Metaphor elicitation method and apparatus |
US5676148A (en) * | 1995-03-31 | 1997-10-14 | Siemens Medical Systems Inc. | Method and system for doppler ultrasound audio dealiasing |
US5717100A (en) * | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
EE03681B1 (et) * | 1995-10-06 | 2002-04-15 | Merck & Co., Inc. | Asendatud imidasoolid, millel on vähivastane ja tsütokiine inhibeeriv toime |
US5676138A (en) * | 1996-03-15 | 1997-10-14 | Zawilinski; Kenneth Michael | Emotional response analyzer system with multimedia display |
AU4618497A (en) * | 1996-08-27 | 1998-03-19 | Novartis Ag | Herbicidal s-substituted 1,2,4,6-thiatriazines |
US6099319A (en) * | 1998-02-24 | 2000-08-08 | Zaltman; Gerald | Neuroimaging as a marketing tool |
US6315569B1 (en) * | 1998-02-24 | 2001-11-13 | Gerald Zaltman | Metaphor elicitation technique with physiological function monitoring |
US6358201B1 (en) * | 1999-03-02 | 2002-03-19 | Doc L. Childre | Method and apparatus for facilitating physiological coherence and autonomic balance |
JP2000302680A (ja) * | 1999-04-23 | 2000-10-31 | Takeda Chem Ind Ltd | 脳保護剤 |
CA2395564A1 (en) * | 1999-11-22 | 2001-05-31 | Smithkline Beecham Plc | Novel compounds |
WO2001052845A1 (en) * | 2000-01-18 | 2001-07-26 | Vertex Pharmaceuticals Incorpoated | Gyrase inhibitors and uses thereof |
AR029803A1 (es) * | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden |
GB0005357D0 (en) | 2000-03-06 | 2000-04-26 | Smithkline Beecham Plc | Compounds |
GB0007405D0 (en) * | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
US6852875B2 (en) * | 2000-05-19 | 2005-02-08 | The Nutrasweet Co. | Synthesis of N-[N-(3,3-dimethylbutyl)-L-α-aspartyl]-L-phenylalanine 1-methyl ester using oxazolidinone derivatives |
US20040053943A1 (en) | 2000-11-20 | 2004-03-18 | Adams Jerry L. | Novel compounds |
ATE341539T1 (de) * | 2001-01-26 | 2006-10-15 | Chugai Pharmaceutical Co Ltd | Malonyl coa-decarboxylase inhibitoren als stoffwechselmodulatoren |
AR039241A1 (es) * | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
AP2005003264A0 (en) * | 2002-09-18 | 2005-03-31 | Pfizer Prod Inc | Novel imidazole compounds as transforming growth factor (TGD) inhibitors. |
AU2004289539C1 (en) | 2003-11-14 | 2012-06-07 | Lorus Therapeutics Inc. | Aryl imidazoles and their use as anti-cancer agents |
MY146532A (en) * | 2004-03-05 | 2012-08-15 | Taisho Pharmaceutical Co Ltd | Thiazole derivative |
KR100749566B1 (ko) * | 2004-04-21 | 2007-08-16 | 이화여자대학교 산학협력단 | Alk5 및/또는 alk4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체 |
WO2005105814A1 (en) * | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
PE20060315A1 (es) * | 2004-05-24 | 2006-05-15 | Irm Llc | Compuestos de tiazol como moduladores de ppar |
US7453002B2 (en) * | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
JP2007246520A (ja) * | 2006-02-15 | 2007-09-27 | Takeda Yuichiro | Rage阻害剤 |
-
2009
- 2009-03-19 BR BRPI0908906A patent/BRPI0908906A2/pt not_active IP Right Cessation
- 2009-03-19 CA CA2718936A patent/CA2718936A1/en not_active Abandoned
- 2009-03-19 KR KR1020137005251A patent/KR20130040258A/ko active IP Right Grant
- 2009-03-19 KR KR1020107023491A patent/KR101408517B1/ko not_active IP Right Cessation
- 2009-03-19 EA EA201001456A patent/EA201001456A1/ru unknown
- 2009-03-19 AU AU2009227013A patent/AU2009227013B2/en not_active Ceased
- 2009-03-19 US US12/383,035 patent/US8129394B2/en not_active Expired - Fee Related
- 2009-03-19 CN CN200980114791.8A patent/CN102015686B/zh not_active Expired - Fee Related
- 2009-03-19 EP EP09722890A patent/EP2274300A2/en not_active Withdrawn
- 2009-03-19 WO PCT/EP2009/053245 patent/WO2009115572A2/en active Application Filing
- 2009-03-19 JP JP2011500226A patent/JP5384611B2/ja not_active Expired - Fee Related
- 2009-03-19 MX MX2010010317A patent/MX2010010317A/es active IP Right Grant
- 2009-03-20 TW TW098109220A patent/TW201000457A/zh unknown
- 2009-03-20 CL CL2009000687A patent/CL2009000687A1/es unknown
- 2009-03-20 AR ARP090101010A patent/AR071283A1/es unknown
- 2009-03-20 PE PE2009000430A patent/PE20091656A1/es not_active Application Discontinuation
- 2009-03-20 UY UY0001031724A patent/UY31724A/es not_active Application Discontinuation
-
2010
- 2010-09-07 IL IL208063A patent/IL208063A0/en unknown
- 2010-09-10 ZA ZA2010/06505A patent/ZA201006505B/en unknown
- 2010-09-20 NI NI201000156A patent/NI201000156A/es unknown
- 2010-09-20 DO DO2010000280A patent/DOP2010000280A/es unknown
- 2010-09-21 SV SV2010003673A patent/SV2010003673A/es not_active Application Discontinuation
- 2010-09-21 CR CR11681A patent/CR11681A/es not_active Application Discontinuation
- 2010-10-15 MA MA33252A patent/MA32232B1/fr unknown
- 2010-10-20 SM SM201000115T patent/SMAP201000115A/it unknown
- 2010-10-21 EC EC2010010559A patent/ECSP10010559A/es unknown
- 2010-10-21 CO CO10130723A patent/CO6311078A2/es not_active Application Discontinuation
-
2013
- 2013-10-02 JP JP2013207483A patent/JP2014040452A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20091656A1 (es) | Compuestos heterociclicos como inhibidores de la cinasa raf | |
PE20140913A1 (es) | Inhibidores de nampt y rock | |
PE20141375A1 (es) | Activadores de glucoquinasa | |
NZ591449A (en) | Picolinamide derivatives as kinase inhibitors | |
PE20091466A1 (es) | Derivados de 4,5-dihidro-oxazol-2-il-amina | |
PE20140865A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
PE20090709A1 (es) | Compuestos heterociclico de 5 miembros | |
PE20090717A1 (es) | Derivados de quinolina como inhibidores de la pi3 quinasa | |
PE20091842A1 (es) | Pirrolidinonas como activadores de glucoquinasa | |
PE20110894A1 (es) | Derivados de pirimidin indol para el tratamiento de cancer | |
PE20151274A1 (es) | Inhibidores de erk y sus usos | |
PE20120693A1 (es) | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) | |
PE20120650A1 (es) | Acetamidas sustituidas por n-(hetero)-arilo y 2-(hetero)-arilo, como moduladores de la senalizacion de wnt | |
PE20090610A1 (es) | Derivados de pirazol sustituidos | |
PE20120861A1 (es) | Compuestos y composiciones como inhibidores de cinasa de proteina | |
PE20121058A1 (es) | Compuestos que modulan el receptor de androgenos | |
PE20140502A1 (es) | Pirimidinas sustituidas de diaminocarboxamida y diaminocarbonitrilo, composiciones de las mismas y metodos de tratamiento con las mismas | |
PE20141004A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
PE20140609A1 (es) | Diazacarbazoles y metodos de uso | |
PE20080404A1 (es) | Derivados bencil-amino-piperidina como inhibidores de cetp | |
PE20110303A1 (es) | Derivados de heteroaril acetamidas como activadores de glucoquinasa | |
EA201000561A1 (ru) | Производные пиридина, пригодные в качестве активаторов глюкокиназы | |
PE20110433A1 (es) | Antagonistas de la via hedgehog de ftalazina disustituida | |
NO20091596L (no) | Benzoylamino-heterocykliske forbindelser som Glucokinase-(GLK)-activatorer | |
EA201200653A1 (ru) | Гетариламинохинолины |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |